Stellar Pharmaceuticals Receives 2nd Uracyst(R) Patent in United States of America
Complete the form below to unlock access to ALL audio articles.
Stellar's second patent issued as United States Patent No. 8,084,441, entitled "Cystitis Treatment with High Dose Chondroitin Sulfate," relates to the treatment of IC/PBS by instillation of an optimized unit dose of chondroitin sulfate that is at least 350mgs or more. The Company expects this patent to issue. Once issued, the patent will expire in 2023.
Rob Harris, Stellar's President and Chief Executive Officer, commented, "This second patent expands the scope of Stellar's exclusive rights in the United States for Uracyst, and further validates the innovative nature of Stellar's approach to the treatment of interstitial cystitis/painful bladder syndrome, and underscores the Company's position as a leader in this field". Mr. Harris went on to say that several companies have expressed an interest in the US rights to Uracyst.